When leukocytoclastic vasculitis is confined to the skin and a clear precipitating cause — a drug reaction or an active infection — can be identified, the clinical approach is shaped by that trigger. This page describes the scenario and the primary goal of care; the full structured protocol is accessible below.
This protocol applies to skin-limited LCV where the episode is attributable to a specific drug or an underlying infection. Most episodes in this setting are self-limited and do not recur once the identifiable cause is removed or treated — making trigger identification the central clinical priority.
The first step centres on addressing the identified trigger. This is combined with supportive physical measures aimed at symptom relief. A pharmacological agent may be added in selected cases where symptomatic management alone is insufficient.
Resolution of cutaneous vasculitis lesions within 3–4 weeks.
DOI: 10.1093/rheumatology/keac115
If LCV is limited to the skin, the management strategy should mostly focus on symptomatic relief, since the majority of acute episodes of cutaneous SVV are self-limited and do not recur, even without treatment.
When the cause of LCV is obvious, such as infections or drugs, eliminating or treating the trigger whenever possible is crucial and often sufficient.
Rest (avoiding prolonged standing or walking) and elevation and use of compression stockings should be advised in all cases.
Therefore, whenever it applies, the definition of "drug-induced" takes on a favorable meaning, since the vasculitis usually remits upon drug discontinuation and will not recur unless it is reintroduced.
Most episodes of single-organ cutaneous LCV are self-limited, resolve over 3–4 weeks, with or without residual hyperpigmentation, and do not recur.
View source ↗